These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 10025846)

  • 21. [Preparation of 131I-VIP and 131I-VIP receptor imaging].
    Shi Y; Tan T
    Hua Xi Yi Ke Da Xue Xue Bao; 2000 Sep; 31(3):292-4. PubMed ID: 12545811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells.
    Jiang S; Kopras E; McMichael M; Bell RH; Ulrich CD
    Cancer Res; 1997 Apr; 57(8):1475-80. PubMed ID: 9108448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Preparation and biodistribution of VIP-125I-ASON].
    Ou XH; Tan TZ; Li YC
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Sep; 36(5):713-6. PubMed ID: 16235546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth.
    Moody TW; Zia F; Draoui M; Brenneman DE; Fridkin M; Davidson A; Gozes I
    Proc Natl Acad Sci U S A; 1993 May; 90(10):4345-9. PubMed ID: 8389448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vasoactive intestinal peptide receptor scintigraphy in patients with pancreatic adenocarcinomas or neuroendocrine tumours.
    Hessenius C; Bäder M; Meinhold H; Böhmig M; Faiss S; Reubi JC; Wiedenmann B
    Eur J Nucl Med; 2000 Nov; 27(11):1684-93. PubMed ID: 11105825
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vasoactive intestinal peptide in cirrhotic rats: hemodynamic effects and mesenteric arterial receptor characteristics.
    Lee SS; Huang M; Ma Z; Rorstad O
    Hepatology; 1996 May; 23(5):1174-80. PubMed ID: 8621151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of vasoactive intestinal polypeptide in the adaptation of intestinal smooth muscle cells to mechanical distension.
    Rekik M; Delvaux M; Frexinos J; Bueno L
    J Pharmacol Exp Ther; 1998 Dec; 287(3):832-8. PubMed ID: 9864261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides.
    Vallabhajosula S; Moyer BR; Lister-James J; McBride BJ; Lipszyc H; Lee H; Bastidas D; Dean RT
    J Nucl Med; 1996 Jun; 37(6):1016-22. PubMed ID: 8683294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.
    Solano RM; Carmena MJ; Carrero I; Cavallaro S; Roman F; Hueso C; Travali S; Lopez-Fraile N; Guijarro LG; Prieto JC
    Endocrinology; 1996 Jul; 137(7):2815-22. PubMed ID: 8770902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Iodine-123-vasoactive intestinal peptide receptor scanning in patients with pancreatic cancer.
    Raderer M; Kurtaran A; Yang Q; Meghdadi S; Vorbeck F; Hejna M; Angelberger P; Kornek G; Pidlich J; Scheithauer W; Virgolini I
    J Nucl Med; 1998 Sep; 39(9):1570-5. PubMed ID: 9744345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis.
    Zawilska JB; Niewiadomski P; Nowak JZ
    Gen Comp Endocrinol; 2004 Jun; 137(2):187-95. PubMed ID: 15158130
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Noninvasive monitoring of gene transfer using a reporter receptor imaged with a high-affinity peptide radiolabeled with 99mTc or 188Re.
    Zinn KR; Buchsbaum DJ; Chaudhuri TR; Mountz JM; Grizzle WE; Rogers BE
    J Nucl Med; 2000 May; 41(5):887-95. PubMed ID: 10809205
    [TBL] [Abstract][Full Text] [Related]  

  • 33. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
    Akesson L; Ahrén B; Edgren G; Degerman E
    Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Localization of iodine-125-mIP-Des-Met14-bombesin (7-13)NH2 in ovarian carcinoma induced to express the gastrin releasing peptide receptor by adenoviral vector-mediated gene transfer.
    Rogers BE; Rosenfeld ME; Khazaeli MB; Mikheeva G; Stackhouse MA; Liu T; Curiel DT; Buchsbaum DJ
    J Nucl Med; 1997 Aug; 38(8):1221-9. PubMed ID: 9255155
    [TBL] [Abstract][Full Text] [Related]  

  • 35. VIP activates G(s) and G(i3) in rat alveolar macrophages and G(s) in HEK293 cells transfected with the human VPAC(1) receptor.
    Shreeve SM; Sreedharan SP; Hacker MP; Gannon DE; Morgan MJ
    Biochem Biophys Res Commun; 2000 Jun; 272(3):922-8. PubMed ID: 10860852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 99mTc(CO)3-VIP analogues: preparation and evaluation as tumor imaging agent.
    Kothari K; Prasad S; Korde A; Mukherjee A; Mathur A; Jaggi M; Venkatesh M; Pillai AM; Mukherjee R; Ramamoorthy N
    Appl Radiat Isot; 2007 Apr; 65(4):382-6. PubMed ID: 17194598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PET imaging of VPAC1 expression in experimental and spontaneous prostate cancer.
    Zhang K; Aruva MR; Shanthly N; Cardi CA; Rattan S; Patel C; Kim C; McCue PA; Wickstrom E; Thakur ML
    J Nucl Med; 2008 Jan; 49(1):112-21. PubMed ID: 18077536
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vasoactive intestinal peptide receptor scintigraphy.
    Virgolini I; Kurtaran A; Raderer M; Leimer M; Angelberger P; Havlik E; Li S; Scheithauer W; Niederle B; Valent P
    J Nucl Med; 1995 Oct; 36(10):1732-9. PubMed ID: 7562036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states.
    Van Rampelbergh J; Gourlet P; De Neef P; Robberecht P; Waelbroeck M
    Mol Pharmacol; 1996 Dec; 50(6):1596-604. PubMed ID: 8967982
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.